Chemed (NYSE: CHE) is expected to report Q4 earnings on Feb. 18. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Chemed's revenues will grow 4.1% and EPS will increase 5.7%.

The average estimate for revenue is $364.5 million. On the bottom line, the average EPS estimate is $1.48.

Revenue details
Last quarter, Chemed reported revenue of $354.4 million. GAAP reported sales were 3.8% higher than the prior-year quarter's $341.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS of $1.07 for Q3 were 2.9% higher than the prior-year quarter's $1.04 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 27.6%, 60 basis points worse than the prior-year quarter. Operating margin was 10.5%, 160 basis points worse than the prior-year quarter. Net margin was 5.9%, 50 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.43 billion. The average EPS estimate is $5.22.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 100 members out of 114 rating the stock outperform, and 14 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Chemed a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $68.75.

Is Chemed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.